First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC

被引：0
|
作者：
J J Ko
T K Choueiri
B I Rini
J-L Lee
N Kroeger
S Srinivas
L C Harshman
J J Knox
G A Bjarnason
M J MacKenzie
L Wood
U N Vaishampayan
N Agarwal
S K Pal
M-H Tan
S Y Rha
T Yuasa
F Donskov
A Bamias
D Y C Heng
机构：
[1] Tom Baker Cancer Center,Department of Oncology
[2] University of Calgary,Department of Urology
[3] Dana Farber Cancer Institute,Division of Oncology
[4] Cleveland Clinic Taussig Cancer Institute,Division of Oncology
[5] Asan Medical Center,Department of Medicine
[6] University of Ulsan College of Medicine,Department of Urology
[7] Universitätsmedizin Greifswald,Department of Oncology
[8] Stanford Medical Center,undefined
[9] Stanford Cancer Institute,undefined
[10] Stanford School of Medicine,undefined
[11] Princess Margaret Cancer Centre,undefined
[12] University Health Network,undefined
[13] University of Toronto,undefined
[14] Sunnybrook Odette Cancer Centre,undefined
[15] University of Toronto,undefined
[16] London Health Sciences Center,undefined
[17] Queen Elizabeth II Health Sciences Centre and Dalhousie University,undefined
[18] Karmanos Cancer Institute,undefined
[19] Wayne State University,undefined
[20] Huntsman Cancer Institute,undefined
[21] University of Utah,undefined
[22] City of Hope Comprehensive Cancer Center,undefined
[23] Medical Oncology & Experimental Therapeutics,undefined
[24] Duarte,undefined
[25] National Cancer Center,undefined
[26] Institute of Bioengineering and Nanotechnology,undefined
[27] Yonsei University Hospital,undefined
[28] Cancer Institute Hospital of Japanese Foundation for Cancer Research,undefined
[29] Aarhus University Hospital,undefined
[30] Alexandra Peripheral General Hospital,undefined
来源：
British Journal of Cancer | 2014年 / 110卷
关键词：
metastatic renal cell carcinoma; targeted molecular therapy; outcomes assessment; overall survival; progression-free survival; mTOR inhibitor; VEGF inhibitor; benchmarks; international metastatic renal cell cancer database consortium;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1917 / 1922
页数：5
相关论文
共 50 条
  • [1] First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC
    Ko, J. J.
    Choueiri, T. K.
    Rini, B. I.
    Lee, J-L
    Kroeger, N.
    Srinivas, S.
    Harshman, L. C.
    Knox, J. J.
    Bjarnason, G. A.
    MacKenzie, M. J.
    Wood, L.
    Vaishampayan, U. N.
    Agarwal, N.
    Pal, S. K.
    Tan, M-H
    Rha, S. Y.
    Yuasa, T.
    Donskov, F.
    Bamias, A.
    Heng, D. Y. C.
    [J]. BRITISH JOURNAL OF CANCER, 2014, 110 (08) : 1917 - 1922
  • [2] First-, second-, third-line therapy for metastatic renal cell carcinoma (mRCC): Benchmarks for trials design from the International mRCC Database Consortium (IMDC)
    Heng, Daniel Yick Chin
    Rini, Brian I.
    Lee, Jae-Lyun
    Kroeger, Nils
    Srinivas, Sandy
    Harshman, Lauren Christine
    Knox, Jennifer J.
    Bjarnason, Georg A.
    MacKenzie, Mary J.
    Wood, Lori
    Vaishampayan, Ulka N.
    Agarwal, Neeraj
    Pal, Sumanta Kumar
    Tan, Min-Han
    Rha, Sun Young
    Yuasa, Takeshi
    Donskov, Frede
    Bamias, Aristotelis
    North, Scott A.
    Choueiri, Toni K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Therapy of malignant melanoma. First-, second- and pathogenesis-oriented third-line therapies
    Rass, K.
    Tadler, D.
    Tilgen, W.
    [J]. HAUTARZT, 2006, 57 (09): : 773 - +
  • [4] Third-line therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)
    Heng, Daniel Yick Chin
    Stukalin, Igor
    Wells, Connor
    Donskov, Frede
    Rini, Brian I.
    Lee, Jae-Lyun
    Bjarnason, Georg A.
    Beuselinck, Benoit
    Smoragiewicz, Martin
    Alva, Ajjai Shivaram
    Srinivas, Sandy
    Wood, Lori
    Brugarolas, James
    Pal, Sumanta Kumar
    Yuasa, Takeshi
    Broom, Reuben James
    Kanesvaran, Ravindran
    Bamias, Aristotelis
    Knox, Jennifer J.
    Choueiri, Toni K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Therapy of malignant melanoma. First-, second- and pathogenesis-oriented third-line therapies [Therapie des metastasierten melanoms. First-, second- und pathogenese-orientierte third-line-therapien]
    Rass K.
    Tadler D.
    Tilgen W.
    [J]. Der Hautarzt, 2006, 57 (9): : 773 - 784
  • [6] Pemetrexed as a Component of First-, Second- and Third-line Chemotherapy in Treating Patients with Metastatic Lung Adenocarcinoma
    Huang, Xin-En
    Tian, Guang-Yu
    Cao, Jie
    Xu, Xia
    Lu, Yan-Yan
    Wu, Xue-Yan
    Liu, Jin
    Shi, Lin
    Xiang, Jin
    [J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (11) : 6663 - 6667
  • [7] First-, second- and third-line chemotherapy for nonsmall cell lung cancer: Patterns of care and cost
    Ramsey, S. D.
    Martins, R.
    Blough, D. K.
    Tock, L.
    Reyes, C.
    Lubeck, D.
    [J]. VALUE IN HEALTH, 2007, 10 (03) : A131 - A131
  • [8] Second- or third-line chemotherapy in NSCLC
    Sorensen, JB
    [J]. LUNG CANCER, 2004, 45 : S18 - S18
  • [9] Second- and third-line therapy in gastric cancer/new options for therapy
    Schmalenberg, H.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 128 - 128
  • [10] Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line
    Leighl, N. B.
    [J]. CURRENT ONCOLOGY, 2012, 19 : S52 - S58
12345